Research programme: cancer drug discovery - Celera Diagnostics/Genentech
Latest Information Update: 03 Aug 2010
At a glance
- Originator Celera Diagnostics; Genentech
- Class Antibodies; Proteins; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Sep 2004 Early research for Cancer in USA (unspecified route)